Ascletis Pharma Hones In on Weight-loss Drug for Further U.S. Studies
MT Newswires Live
Oct 13
Ascletis Pharma (HKG:1672) said it had selected a once-monthly version of ASC35 for further studies in the U.S., according to a Hong Kong bourse filing Monday.
The company plans to seek U.S. regulatory approval to begin human trials of the subcutaneous version of the drug to treat obesity.
An investigational new drug application is expected in the second quarter of 2026, the firm said.
According to Ascletis, animal studies showed its medicine was superior to Eli Lilly's (LLY) weight-loss drug tirzepatide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.